Lessons from seven decades of antituberculosis drug discovery

Current Topics in Medicinal Chemistry

Volumn 11, Issue 10, 2011, Pages 1216-1225

  Barry, Clifton E ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Benzothiazinone; Diarylquinoline; Drug development; Isoniazid; Linezolid; Nitroimidazoles; Rifampicin; Streptomycin; Tuberculosis

Indexed keywords

2 NITROIMIDAZOLE; 4 NITROIMIDAZOLE; AMIKACIN; BENZOTHIAZINE DERIVATIVE; CELL ENZYME; ETHIONAMIDE; ISONIAZID; KANAMYCIN; LINEZOLID; METRONIDAZOLE; NICOTINAMIDE; OXAZOLIDINONE DERIVATIVE; PROTIONAMIDE; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; THIOACETAZONE; THIOSEMICARBAZONE DERIVATIVE; TUBERCULOSTATIC AGENT; UNSPECIFIC MONOOXYGENASE;

BACTERIAL MEMBRANE; BACTERIAL METABOLISM; CELL ACTIVITY; CELL DEATH; CELL SCREENING; DEPRESSION; DRUG ACTIVITY; DRUG EFFICACY; DRUG ISOLATION; DRUG MARKETING; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; ESCHERICHIA COLI; GENOTOXICITY; HAEMOPHILUS INFLUENZAE; HISTORY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MONOTHERAPY; MULTIDRUG RESISTANT TUBERCULOSIS; PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN SYNTHESIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SALMONELLA TYPHIMURIUM; TREATMENT DURATION; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT;

ANTITUBERCULAR AGENTS; DRUG DESIGN; DRUG DISCOVERY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS;

EID: 79960062811     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/156802611795429158     Document Type: Review

References (73)

1. Donoghue, H. D.; Spigelman, M.; Greenblatt, C. L.; Lev-Maor, G.; Bar-Gal, G. K.; Matheson, C.; Vernon, K.; Nerlich, A. G.; Zink, A. R. Tuberculosis: from prehistory to Robert Koch, as revealed by ancient DNA. Lancet Infect. Dis., 2004, 4, 584-592.
2. Glaziou, P.; Floyd, K.; Raviglione, M. Global burden and epidemiology of tuberculosis. Clin. Chest Med., 2009, 30, 621-36, vii.
3. Aziz, M. A.; Wright, A.; Laszlo, A.; De Muynck, A.; Portaels, F.; Van Deun, A.; Wells, C.; Nunn, P.; Blanc, L.; Raviglione, M. Epidemiology of antituberculosis drug resistance (the Global Project on Anti-tuberculosis Drug Resistance Surveillance): an updated analysis. Lancet, 2006, 368, 2142-2154.
4. Riccardi, G.; Pasca, M. R.; Buroni, S. Mycobacterium tuberculosis: drug resistance and future perspectives. Future Microbiol., 2009, 4, 597-614.
5. Wright, A.; Zignol, M.; Van Deun, A.; Falzon, D.; Gerdes, S. R.; Feldman, K.; Hoffner, S.; Drobniewski, F.; Barrera, L.; van Soolingen, D.; Boulabhal, F.; Paramasivan, C. N.; Kam, K. M.; Mitarai, S.; Nunn, P.; Raviglione, M. Epidemiology of antituberculosis drug resistance 2002-07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Lancet, 2009, 373, 1861-1873.
6. Maher, D.; Dye, C.; Floyd, K.; Pantoja, A.; Lonnroth, K.; Reid, A.; Nathanson, E.; Pennas, T.; Fruth, U.; Cunningham, J.; Ignatius, H.; Raviglione, M. C.; Koek, I.; Espinal, M. Planning to improve global health: the next decade of tuberculosis control. Bull World Health Organ., 2007, 85, 341-347.
7. Lo Bue, P. Extensively drug-resistant tuberculosis. Curr. Opin. Infect. Dis., 2009, 22, 167-173.
8. Shah, N. S.; Wright, A.; Bai, G. H.; Barrera, L.; Boulahbal, F.; Martin-Casabona, N.; Drobniewski, F.; Gilpin, C.; Havelkova, M.; Lepe, R.; Lumb, R.; Metchock, B.; Portaels, F.; Rodrigues, M. F.; Rusch-Gerdes, S.; Van Deun, A.; Vincent, V.; Laserson, K.; Wells, C.; Cegielski, J. P. Worldwide emergence of extensively drugresistant tuberculosis. Emerg. Infect. Dis., 2007, 13, 380-387.
9. Caminero, J. A. Likelihood of generating MDR-TB and XDR-TB under adequate National Tuberculosis Control Programme implementation. Int. J. Tuberc. Lung. Dis., 2008, 12, 869-877.
10. Schatz, A.; Waksman, S. A. Effect of streptomycin and other antibiotic substances upon Mycobacterium tuberculosis and related organisms. Proc. Expt. Biol. Med., 1944, 57, 244-248.
11. Daniel, T. M. Selman Abraham Waksman and the discovery of streptomycin. Int. J. Tuberc. Lung Dis., 2005, 9, 120-122.
12. Crofton, J. The MRC randomized trial of streptomycin and its legacy: a view from the clinical front line. J. R. Soc. Med., 2006, 99, 531-534.
13. Kuehl, F. A., Jr.; Peck, R. L. Streptomyces antibiotics; structure of streptomycin. J. Am. Chem. Soc., 1948, 70, 2325-2330.
14. Umezawa, H.; Ueda, M.; Maeda, K.; Yagishita, K.; Kondo, S.; Okami, Y.; Utahara, R.; Osato, Y.; Nitta, K.; Takeuchi, T. Production and isolation of a new antibiotic: kanamycin. J. Antibiot., (Tokyo) 1957, 10, 181-188.
15. Price, K. E.; Pursiano, T. A.; DeFuria, M. D. Activity of BB-K8 (amikacin) against clinical isolates resistant to one or more aminoglycoside antibiotics. Antimicrob. Agents Chemother., 1974, 5, 143-152.
16. Jeon, C. Y.; Hwang, S. H.; Min, J. H.; Prevots, D. R.; Goldfeder, L. C.; Lee, H.; Eum, S. Y.; Jeon, D. S.; Kang, H. S.; Kim, J. H.; Kim, B. J.; Kim, D. Y.; Holland, S. M.; Park, S. K.; Cho, S. N.; Barry, C. E., 3rd; Via, L. E. Extensively drug-resistant tuberculosis in South Korea: risk factors and treatment outcomes among patients at a tertiary referral hospital. Clin. Infect. Dis., 2008, 46, 42-49.
17. Via, L. E.; Lin, P. L.; Ray, S. M.; Carrillo, J.; Allen, S. S.; Eum, S. Y.; Taylor, K.; Klein, E.; Manjunatha, U.; Gonzales, J.; Lee, E. G.; Park, S. K.; Raleigh, J. A.; Cho, S. N.; McMurray, D. N.; Flynn, J. L.; Barry, C. E., 3rd. Tuberculous granulomas are hypoxic in guinea pigs, rabbits, and nonhuman primates. Infect. Immun., 2008, 76, 2333-2340.
18. Fischbach, M. A.; Walsh, C. T. Antibiotics for emerging pathogens. Science, 2009, 325, 1089-1093.
19. Lichtenthaler, F. W. Emil Fischer, his personality, his achievements, and his scientific progeny. Eur. J. Organ. Chem., 2002, 4095-4122.
20. Meyer, H.; Mally, J. Uber pydrazinderivate der pyridincarbonsauren. Monatsschr Chemie, 1912, 33, 393-414.
21. Rieder, H. L. Fourth-generation fluoroquinolones in tuberculosis. Lancet, 2009, 373, 1148-1149.
22. Sandler, M. Monoamine oxidase inhibitors in depression: history and mythology. J. Psychopharmacol., 1990, 4, 136-139.
23. Domagk, G. Investigations on the antituberculous activity of the thiosemicarbazones in vitro and in vivo. Am. Rev. Tuberc., 1950, 61, 8-19.
24. Sneader, W. Drug discovery: The evolution of modern medicines. John Wiley & Sons Inc.: Somerset, New Jersey, USA, 1985.
25. Grunberg, E.; Schnitzer, R. J.; Eldridge, D.; Unger, C.; Titsworth, E. The effect of hydrazine derivatives of isonicotinic acid on the infection of mice with m-tuberculosis var-bovis. Yale J. Biol. Med., 1952, 24, 359-365.
26. Grunberg, E.; Leiwant, B.; Dascensio, I. L.; Schnitzer, R. J. On the lasting protective effect of hydrazine derivatives of isonicotinic acid in the experimental tuberculosis infection of mice. Dis. Chest, 1952, 21, 369-377.
27. Lopez-Munoz, F.; Alamo, C. Monoaminergic neurotransmission: the history of the discovery of antidepressants from 1950s until today. Curr. Pharm. Des., 2009, 15, 1563-1586.
28. Argyrou, A.; Vetting, M. W.; Aladegbami, B.; Blanchard, J. S. Mycobacterium tuberculosis dihydrofolate reductase is a target for isoniazid. Nat. Struct. Mol. Biol., 2006, 13, 408-413.
29. 3rd.; Slayden, R. A.; Mdluli, K. Mechanisms of isoniazid resistance in Mycobacterium tuberculosis. Drug Resist. Updat 1998, 1, 128-34.
30. DeBarber, A. E.; Mdluli, K.; Bosman, M.; Bekker, L. G.; Barry, C. E., 3rd. Ethionamide activation and sensitivity in multidrugresistant Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. USA, 2000, 97, 9677-82.
31. 3rd. Effects of pyrazinamide on fatty acid synthesis by whole mycobacterial cells and purified fatty acid synthase I. J. Bacteriol., 2002, 184, 2167-2172.
32. Sensi, P.; Greco, A. M.; Ballotta, R. Rifomycin. I. Isolation and properties of rifomycin B and rifomycin complex. Antibiot. Annu., 1959, 7, 262-270.
33. Sensi, P.; Ballotta, R.; Greco, M. Rifomycin. V. Rifomycin O, a new antibiotic of the rifomycin family. Farmaco Sci., 1960, 15, 228-234.
34. Sensi, P.; Timbal, M. T.; Maffii, G. Rifomycin IX. Two new antibiotics of rifomycin family: rifomycin S and rifomycin SV. Preliminary report. Experientia, 1960, 16, 412.
35. Anschel, R. Use and action of the new antibiotic rifamycin Sv (Rifocin). Wien Med. Wochenschr., 1965, 115, 197-202.
36. Sensi, P. History of the development of rifampin. Rev. Infect. Dis., 1983, 5(Suppl 3), S402-406.
37. Maggi, N.; Arioli, V.; Sensi, P.; Rifamycins, X. L. I. A new class of active semisynthetic rifamycins. N-substituted aminomethyl derivatives of rifamycin SV 2. J. Med. Chem., 1965, 8, 790-793.
38. Maggi, N.; Pasqualucci, C. R.; Ballotta, R.; Sensi, P. Rifampicin: a new orally active rifamycin. Chemotherapy, 1966, 11, 285-292.
39. Fox, W.; Mitchison, D. A. Short-course chemotherapy for pulmonary tuberculosis. Am. Rev. Respir. Dis., 1975, 111, 845-848.
40. Short-course chemotherapy in pulmonary tuberculosis. A controlled trial by the British Thoracic and Tuberculosis Association. Lancet, 1975, 1, 119-124.
41. Controlled clinical trial of four short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Third report. East African-British Medical Research Councils. Lancet, 1974, 2, 237-240.
42. Brickner, S. J. Oxazolidinone antibacterial agents. Curr. Pharm. Des., 1996, 2, 175-194.
43. Brickner, S. J.; Barbachyn, M. R.; Hutchinson, D. K.; Manninen, P. R. Linezolid (ZYVOX), the first member of a completely new class of antibacterial agents for treatment of serious gram-positive infections. J. Med. Chem., 2008, 51, 1981-1990.
44. Gleave, D. M.; Brickner, S. J.; Manninen, P. R.; Allwine, D. A.; Lovasz, K. D.; Rohrer, D. C.; Tucker, J. A.; Zurenko, G. E.; Ford, C. W. Synthesis and antibacterial activity of [6,5,5] and [6,6,5] tricyclic fused oxazolidinones. Bioorg. Med. Chem. Lett., 1998, 8, 1231-1236.
45. Renslo, A. R.; Luehr, G. W.; Gordeev, M. F. Recent developments in the identification of novel oxazolidinone antibacterial agents. Bioorg. Med. Chem., 2006, 14, 4227-4240.
46. Williams, K. N.; Stover, C. K.; Zhu, T.; Tasneen, R.; Tyagi, S.; Grosset, J. H.; Nuermberger, E. Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model. Antimicrob. Agents Chemother., 2009, 53, 1314-1319.
47. Williams, K. N.; Brickner, S. J.; Stover, C. K.; Zhu, T.; Ogden, A.; Tasneen, R.; Tyagi, S.; Grosset, J. H.; Nuermberger, E. L. Addition of PNU-100480 to first-line drugs shortens the time needed to cure murine tuberculosis. Am. J. Respir. Crit. Care Med., 2009, 180, 371-376.
48. Sood, R.; Bhadauriya, T.; Rao, M.; Gautam, R.; Malhotra, S.; Barman, T. K.; Upadhyay, D. J.; Rattan, A. Antimycobacterial activities of oxazolidinones: a review. Infect. Disord. Drug Targets, 2006, 6, 343-354.
49. Vinh, D. C.; Rubinstein, E. Linezolid: a review of safety and tolerability. J. Infect., 2009, 59(Suppl 1), S59-74.
50. Wimberly, B. T. The use of ribosomal crystal structures in antibiotic drug design. Curr. Opin. Investig. Drugs, 2009, 10, 750-765.
51. Ippolito, J. A.; Kanyo, Z. F.; Wang, D.; Franceschi, F. J.; Moore, P. B.; Steitz, T. A.; Duffy, E. M. Crystal structure of the oxazolidinone antibiotic linezolid bound to the 50S ribosomal subunit. J. Med. Chem., 2008, 51, 3353-3356.
52. Barry, C. E., 3rd; Boshoff, H. I.; Dowd, C. S. Prospects for clinical introduction of nitroimidazole antibiotics for the treatment of tuberculosis. Curr. Pharm. Des., 2004, 10, 3239-3262.
53. Ashtekar, D. R.; Costa-Perira, R.; Nagrajan, K.; Vishvanathan, N.; Bhatt, A. D.; Rittel, W. In vitro and in vivo activities of the nitroimidazole CGI 17341 against Mycobacterium tuberculosis. Antimicrob. Agents Chemother., 1993, 37, 183-186.
54. Hickey, M. J.; Arain, T. M.; Shawar, R. M.; Humble, D. J.; Langhorne, M. H.; Morgenroth, J. N.; Stover, C. K. Luciferase in vivo expression technology: use of recombinant mycobacterial reporter strains to evaluate antimycobacterial activity in mice. Antimicrob. Agents Chemother., 1996, 40, 400-407.
55. Stover, C. K.; Warrener, P.; VanDevanter, D. R.; Sherman, D. R.; Arain, T. M.; Langhorne, M. H.; Anderson, S. W.; Towell, J. A.; Yuan, Y.; McMurray, D. N.; Kreiswirth, B. N.; Barry, C. E.; Baker, W. R. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature, 2000, 405, 962-966.
56. Matsumoto, M.; Hashizume, H.; Tomishige, T.; Kawasaki, M.; Tsubouchi, H.; Sasaki, H.; Shimokawa, Y.; Komatsu, M. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med., 2006, 3, e466.
57. Sasaki, H.; Haraguchi, Y.; Itotani, M.; Kuroda, H.; Hashizume, H.; Tomishige, T.; Kawasaki, M.; Matsumoto, M.; Komatsu, M.; Tsubouchi, H. Synthesis and antituberculosis activity of a novel series of optically active 6-nitro-2,3-dihydroimidazo[2,1-b]oxazoles. J. Med. Chem., 2006, 49, 7854-7860.
58. Wayne, L. G.; Sohaskey, C. D. Nonreplicating persistence of Mycobacterium tuberculosis. Annu. Rev. Microbiol., 2001, 55, 139-163.
59. 3rd. Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. USA, 2006, 103, 431-436.
60. Kim, P.; Zhang, L.; Manjunatha, U. H.; Singh, R.; Patel, S.; Jiricek, J.; Keller, T. H.; Boshoff, H. I.; Barry, C. E.; Dowd, C. S. Structure-activity relationships of antitubercular nitroimidazoles. 1. Structural features associated with aerobic and anaerobic activities of 4-and 5-nitroimidazoles. J. Med. Chem., 2009, 52, 1317-1328.
61. Singh, R.; Manjunatha, U.; Boshoff, H. I.; Ha, Y. H.; Niyomrattanakit, P.; Ledwidge, R.; Dowd, C. S.; Lee, I. Y.; Kim, P.; Zhang, L.; Kang, S.; Keller, T. H.; Jiricek, J.; Barry, C. E., 3rd. PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release. Science, 2008, 322, 1392-1395.
62. Diacon, A. H.; Pym, A.; Grobusch, M.; Patientia, R.; Rustomjee, R.; Page-Shipp, L.; Pistorius, C.; Krause, R.; Bogoshi, M.; Churchyard, G.; Venter, A.; Allen, J.; Palomino, J. C.; De Marez, T.; van Heeswijk, R. P.; Lounis, N.; Meyvisch, P.; Verbeeck, J.; Parys, W.; de Beule, K.; Andries, K.; McNeeley, D. F. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N. Engl. J. Med., 2009, 360, 2397-2405.
63. 3rd.; Unorthodox approach to the development of a new antituberculosis therapy. N. Engl. J. Med., 2009, 360, 2466-2467.
64. Andries, K.; Verhasselt, P.; Guillemont, J.; Gohlmann, H. W.; Neefs, J. M.; Winkler, H.; Van Gestel, J.; Timmerman, P.; Zhu, M.; Lee, E.; Williams, P.; de Chaffoy, D.; Huitric, E.; Hoffner, S.; Cambau, E.; Truffot-Pernot, C.; Lounis, N.; Jarlier, V. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science, 2005, 307, 223-227.
65. Koul, A.; Vranckx, L.; Dendouga, N.; Balemans, W.; Van den Wyngaert, I.; Vergauwen, K.; Gohlmann, H. W.; Willebrords, R.; Poncelet, A.; Guillemont, J.; Bald, D.; Andries, K. Diarylquinolines are bactericidal for dormant mycobacteria as a result of disturbed ATP homeostasis. J. Biol. Chem., 2008, 283, 25273-25280.
66. Rao, S. P.; Alonso, S.; Rand, L.; Dick, T.; Pethe, K. The protonmotive force is required for maintaining ATP homeostasis and viability of hypoxic, nonreplicating Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. USA, 2008, 105, 11945-11950.
67. Makarov, V.; Manina, G.; Mikusova, K.; Möllmann, U.; Ryabova, O.; Saint-Joanis, B.; Dhar, N.; Pasca, M. R.; Buroni, S.; Lucarelli, A.P.; Milano, A.; De Rossi, E.; Belanova, M.; Bobovska, A.; Dianiskova, P.; Kordulakova, J.; Sala, C.; Fullam, E.; Schneider, P.; McKinney, J. D.; Brodin, P.; Christophe, T.; Waddell, S.; Butcher, P.; Albrethsen, J.; Rosenkrands, I.; Brosch, R.; Nandi, V.; Bharath, S.; Gaonkar, S.; Shandil, R. K.; Balasubramanian, V.; Balganesh, T.; Tyagi, S.; Grosset, J.; Riccardi, G.; Cole, S. T. Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis. Science, 2009, 324, 801-804.
68. Christophe, T.; Jackson, M.; Jeon, H. K.; Fenistein, D.; Contreras-Dominguez, M.; Kim, J.; Genovesio, A.; Carralot, J. P.; Ewann, F.; Kim, E. H,; Lee, S. Y.; Kang, S.; Seo, M. J.; Park, E. J.; Skovierová, H.; Pham, H.; Riccardi, G.; Nam, J. Y.; Marsollier, L.; Kempf, M.; Joly-Guillou, M. L.; Oh, T.; Shin, W. K.; No, Z.; Nehrbass, U.; Brosch, R.; Cole, S. T.; Brodin, P. High content screening identifies decaprenyl-phosphoribose 2' epimerase as a target for intracellular antimycobacterial inhibitors. PLoS Pathog., 2009, 5(10), e1000645.
69. de Jonge, M. R.; Koymans, L. H.; Guillemont, J. E.; Koul, A.; Andries, K. A computational model of the inhibition of Mycobacterium tuberculosis ATPase by a new drug candidate R207910. Proteins, 2007, 67, 971-980.
70. Kohanski, M. A.; Dwyer, D. J.; Wierzbowski, J.; Cottarel, G.; Collins, J. J. Mistranslation of membrane proteins and twocomponent system activation trigger antibiotic-mediated cell death. Cell, 2008, 135, 679-690.
71. Dwyer, D. J.; Kohanski, M. A.; Collins, J. J. Role of reactive oxygen species in antibiotic action and resistance. Curr. Opin. Microbiol., 2009, 12, 482-489.
72. Miller, J. R.; Dunham, S.; Mochalkin, I.; Banotai, C.; Bowman, M.; Buist, S.; Dunkle, B.; Hanna, D.; Harwood, H. J.; Huband, M. D.; Karnovsky, A.; Kuhn, M.; Limberakis, C.; Liu, J. Y.; Mehrens, S.; Mueller, W. T.; Narasimhan, L.; Ogden, A.; Ohren, J.; Prasad, J. V.; Shelly, J. A.; Skerlos, L.; Sulavik, M.; Thomas, V. H.; VanderRoest, S.; Wang, L.; Wang, Z.; Whitton, A.; Zhu, T.; Stover, C. K. A class of selective antibacterials derived from a protein kinase inhibitor pharmacophore. Proc. Natl. Acad. Sci. USA, 2009, 106, 1737-1742.
73. Mochalkin, I.; Miller, J. R.; Narasimhan, L.; Thanabal, V.; Erdman, P.; Cox, P. B.; Prasad, J. V.; Lightle, S.; Huband, M. D.; Stover, C. K. Discovery of antibacterial biotin carboxylase inhibitors by virtual screening and fragment-based approaches. ACS Chem. Biol., 2009, 4, 473-83.